Johnson & Johnson Coronavirus Vaccine Illustration
Given Ruvic | Reuters
According to trial data published in the New England Journal of Medicine on Wednesday, one dose of Johnson & Johnson’s coronavirus vaccine is safe and appears to have produced a promising immune response in both young and elderly volunteers.
Johnson & Johnson scientists randomly assigned healthy adults between the ages of 1
According to experimental data, most volunteers produced detectable neutralizing antibodies. Researchers believe that after 28 days, these antibodies play an important role in protecting cells against viruses. By day 57, all volunteers had detectable antibodies regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18 to 55-year-old age group.
According to test data, the most common side effects are fever, fatigue, headache, muscle pain and pain at the injection site. The data shows that side effects are less common in elderly people who receive only one dose of vaccine and those who receive lower doses of vaccine.
In an interview with CNBC reporter Meg Tirrell, Dr. Paul Stoffels, chief scientific officer of Johnson & Johnson, said that the first and second phase clinical trial data showed that the vaccine “has sustainable antibodies.” He added that this gives the company “confidence” that the vaccine will be very effective against this virus.
The trial tested 805 volunteers. The company is expected to release the results of its 45,000-person Phase 3 trial later this month. Johnson & Johnson uses the same technology as the Covid-19 vaccine to develop the Ebola vaccine.
US officials and Wall Street analysts are eagerly awaiting the authorization of Johnson & Johnson vaccine, which may begin as early as next month. Public health officials and infectious disease experts say that world leaders will need a series of drugs and vaccines to fight the virus. Since the beginning of the pandemic, the virus has killed at least 382,120 Americans.
If Johnson & Johnson’s vaccine is authorized by the US Food and Drug Administration (FDA), it will be the third vaccine approved in the United States after Pfizer’s BioNTech vaccine and Moderna vaccine. Pfizer’s vaccine was authorized on December 11, and Moderna’s vaccine was authorized a week later on December 18.
When the data was released, US officials complained that because the supply of vaccine doses exceeded demand, the rate of vaccination was too slow. The Centers for Disease Control and Prevention on Tuesday expanded the Covid vaccine eligibility guidelines to include people 65 years and older and people with pre-existing diseases. The government has also changed the way the Covid vaccine dose is allocated, which is now based on the rate of vaccine injection in each state and the number of elderly populations.
The official said that the Trump administration will no longer retain the millions of doses reserved for the second round of Pfizer and Moderna’s two-dose vaccines, adding that they have released the doses that they had reserved on Sunday. President-elect Biden’s transition team announced a similar plan Friday.
Unlike Pfizer and Moderna’s licensed vaccines, which require two doses about three to four weeks apart, Johnson & Johnson only needs one dose. This means that patients will no longer have to receive another dose of treatment, thus simplifying the logistics of medical service providers.
The Ministry of Health and Human Services announced in August that it had reached an agreement with Janssen, a pharmaceutical subsidiary of Johnson & Johnson, for its 100 million doses of vaccines worth approximately US$1 billion. The announcement stated that the transaction gives the federal government the option to order another 200 million doses.
Stoffels said the company plans to ship vaccines at 2 to 8 degrees Celsius (about 36 to 46 degrees Fahrenheit).
He said: “As of now, we have 3 months of stable time 2 to 8.” “As we generate more stability data, this number will expand in a year. We know from other vaccines that it can be used One year, but at the beginning we can’t do this because we don’t have this vaccine.”